Sat, Feb 28, 2015, 12:30 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

  • inversor86 inversor86 May 1, 2014 12:58 PM Flag

    Shouldn't Prana have PR'd something about the two new Phase 1 trials?

    Am I off base? This is a time when it is crucial that this company keeps the market informed about updates, changes, progress etc. Not addressing these two new trials has only raised more questions for me. This is a terrible time to give shareholders addition items to question or draw their own conclusions about.

    Right now I've drawn three conclusions; 1. This will only lengthen the time before a Phase III HD trial can begin, along with all the other benefits that go along with starting that trial. 2. The need for these new trials stems from some "hindsight" realization after the failures of the Imagine trial. 3. Kempler is demonstrating more poor leadership abilities by not taking this opportunity to issue a progress update.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • What I think here is that PBT2 needs to get accepted by FDA and so the metabolism in a human body needs to be studied. The metabolism can be different in some people than in most of us.
      One important enzyme in pharmacokinetics of drugs is CYP1A2. Measuring CYP1A2 activity in vivo can be an important tool to identify the factors that influence variability in drug pharmacokinetics and inform dose selection. Caffeine is the only currently accepted probe to conduct in vivo phenotyping of CYP1A2 .

      So clearly Prana is now closer to send it's papers to FDA. I still think that ReachHD results could be enough for efficacy but now these pharmacokinetic studies are missing, but not for long.

 
PRAN
1.11-0.060(-5.12%)Feb 27 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.